Lilly’s path to redemption: Turn new drugs into sales

Back to TopCommentsE-mailPrintBookmark and Share

The numbers this year will be bad for Eli Lilly and Co.; there’s no getting around that.

In the past 2 1-2 years, the Indianapolis-based drugmaker has watched patents expire on not one, but two $5 billion-a-year drugs. That will send Lilly profit tumbling an estimated 32 percent this year.

But 2014 will also give Lilly an opportunity it hasn’t really had for nearly a decade: to grow sales and profit by launching new drugs.

Wall Street analysts say Lilly could win approval from the U.S. Food and Drug Administration for four new drugs: ramucirumab for gastric cancer, necitumumab for lung cancer, and dulaglutide and empagliflozin—both for diabetes.

“We continue to view Lilly as an earnings recovery story and while we do not anticipate near-term outperformance for the stock, we could see a longer-term opportunity for LLY shares to the extent the company is able to successfully commercialize its next-generation product portfolio and maintain cost discipline over the next several years,” Chris Schott, a pharmaceutical analyst at J.P. Morgan, said in a Jan. 30 note to investors.

Since 2005, Lilly has launched just three new drugs—none of them remarkable. The blood thinner Effient, once expected to be a blockbuster, had 2013 sales of $509 million. The diabetes pill Tradjenta, developed by Lilly partner Boehringer Ingelheim GmbH, had sales last year of just $249 million.

Lilly also helped a Japanese firm launch a cholesterol drug, Livalo, in 2010, but that relationship ended.

Some of the things that limited those drugs could hamper Lilly’s new drugs: Competing products, some already in a cheap generic form, do similar things.

Also, state-run health plans in foreign countries and private health plans in the United States are scrutinizing new drugs more aggressively before agreeing to reimburse patients, and narrowing their formularies to favor generic drugs and drugs discounted by the companies that make them.

Also, far more U.S. physicians are now employed by hospital systems, which are also pushing drugmakers to prove their drugs are superior before agreeing to allow their doctors to use them.

All those factors mean it will take Lilly longer to ramp up sales of new drugs—if it’s able to ramp them up at all.

Jami Rubin, a pharmaceutical analyst at Goldman Sachs, expects Lilly’s four new drugs to bring in sales this year of $261 million, with that total rising to $1.9 billion in 2017.

But that same year, Lilly stands to lose its patent on Cialis, its $2 billion-a-year pill for impotence, which would offset gains of the drugs launched this year.

Analysts have been repeatedly impressed with Lilly’s ability to wring additional revenue out of existing products. In the fourth quarter of 2013, for example, Lilly raised U.S. prices 10 percent, helping hold overall revenue fairly flat—even though U.S. patents on its bestseller Cymbalta expired in December.

Lilly will have to apply some of that magic to its new products if it hopes to reverse generally negative views on Wall Street. Twelve of 20 analysts rate Lilly a hold or worse, according to a Thomson/First Call survey.

“Given the still-skeptical view of LLY by the majority of investors, and what still seems to be under-ownership of the name, there is more ‘runway’ left should additional investors turn positive, which itself will be a function of LLY executing on various fronts, the most important of which is its pipeline,” Tim Anderson, a pharmaceutical analyst at Bernstein Research, wrote in a Jan. 31 note to investors.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help